Anti-TNF-alpha therapy in ankylosing spondylitis

被引：20

作者：

De Keyser, F ^{[1
]}

Van den Bosch, F ^{[1
]}

Mielants, H ^{[1
]}

机构：

[1] State Univ Ghent Hosp, Dept Rheumatol, B-9000 Ghent, Belgium

来源：

CYTOKINE | 2006年 / 33卷 / 05期

关键词：

infliximab; etanercept; ankylosing spondylitis;

D O I：

10.1016/j.cyto.2006.01.004

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Ankylosing spondylitis (AS) is the prototype disease within the spondyloarthropathies (SpA), a group of diseases presenting mainly with spondylitis, pauci-articular peripheral arthritis and enthesiopathy. Non-steroidal anti-inflammatory drugs (NSAID) are the classical cornerstone of medical therapy in these patients; no real disease modifying antirheumatic treatment was available, until recently. TNF-alpha blocking agents (monoclonal antibodies or soluble receptors) are the first representative drugs, of which the indication has recently been expanded to encompass also patients with AS. Here, we review the data on clinical efficacy and safety, with focus on the compounds infliximab and etanercept. Publication of trial results with adalimumab is still under way; the efficacy of this compound in AS seems comparable with the other two agents. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：294 / 298

页数：5

共 25 条

[1] Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? [J].

Baeten, D ;

Kruithof, E ;

Van den Bosch, F ;

Van den Bossche, N ;

Herssens, A ;

Mielants, H ;

De Keyser, F ;

Veys, EM .

ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (09) :829-834

[2]

Boulware D., 2003, CLIN PRIMER RHEUMATO, P127

[3] Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis [J].

Brandt, J ;

Khariouzov, A ;

Listing, J ;

Haibel, H ;

Sörensen, H ;

Grassnickel, L ;

Rudwaleit, M ;

Sieper, J ;

Braun, J .

ARTHRITIS AND RHEUMATISM, 2003, 48 (06) :1667-1675

[4] Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial [J].

Braun, J ;

Brandt, J ;

Listing, J ;

Zink, A ;

Alten, R ;

Golder, W ;

Gromica-Ihle, E ;

Kellner, H ;

Krause, A ;

Schneider, M ;

Sörensen, H ;

Zeidler, H ;

Thriene, W ;

Sieper, J .

LANCET, 2002, 359 (9313) :1187-1193

[5] USE OF DYNAMIC MAGNETIC-RESONANCE-IMAGING WITH FAST IMAGING IN THE DETECTION OF EARLY AND ADVANCED SACROILIITIS IN SPONDYLARTHROPATHY PATIENTS [J].

BRAUN, J ;

BOLLOW, M ;

EGGENS, U ;

KONIG, H ;

DISTLER, A ;

SIEPER, J .

ARTHRITIS AND RHEUMATISM, 1994, 37 (07) :1039-1045

[6] USE OF IMMUNOHISTOLOGIC AND IN-SITU HYBRIDIZATION TECHNIQUES IN THE EXAMINATION OF SACROILIAC JOINT BIOPSY SPECIMENS FROM PATIENTS WITH ANKYLOSING-SPONDYLITIS [J].

BRAUN, J ;

BOLLOW, M ;

NEURE, L ;

SEIPELT, E ;

SEYREKBASAN, F ;

HERBST, H ;

EGGENS, U ;

DISTLER, A ;

SIEPER, J .

ARTHRITIS AND RHEUMATISM, 1995, 38 (04) :499-505

[7] Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis [J].

Calin, A ;

Dijkmans, BAC ;

Emery, P ;

Hakala, M ;

Kalden, J ;

Leirisalo-Repo, M ;

Mola, EM ;

Salvarani, C ;

Sanmartí, R ;

Sany, J ;

Sibilia, J ;

Sieper, J ;

van der Linden, S ;

Veys, E ;

Appel, AM ;

Fatenejad, S .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (12) :1594-1600

[8] Recombinant human tumor necrosis factor receptor, (etanercept) for treating ankylosing spondylitis - A randomized, controlled trial [J].

Davis, JC ;

van der Heijde, D ;

Braun, J ;

Dougados, M ;

Cush, J ;

Clegg, DO ;

Kivitz, A ;

Fleischmann, R ;

Inman, R ;

Tsuji, W .

ARTHRITIS AND RHEUMATISM, 2003, 48 (11) :3230-3236

[9]

De Keyser F, 2003, J RHEUMATOL, V30, P2306

[10] Bowel inflammation and the spondyloarthropathies [J].

De Keyser, F ;

Elewaut, D ;

De Vos, M ;

De Vlam, K ;

Cuvelier, C ;

Mielants, H ;

Veys, EM .

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1998, 24 (04) :785-+

← 1 2 3 →